Friday, December 8, 2023, 7:00 PM – 9:00 PM PT (10:00 PM – 12:00 AM ET)

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Multiple Myeloma (Part 4 of a 4-Part Series)

A CME Friday Satellite Symposium and Virtual Event Preceding the 65th ASH Annual Meeting

Location
Omni San Diego Hotel
675 L Street
San Diego, CA 92101
Phone: (619) 231-6664

Program Schedule — Pacific Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Diego, preregistration is required as seating is limited.  
 
Faculty
Amrita Krishnan, MD
Director of the Judy and Bernard Briskin
Center for Multiple Myeloma Research
Professor of Hematology/Hematopoietic Cell Transplantation
City of Hope Cancer Center
Duarte, California

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Paul G Richardson, MD
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AbbVie Inc, GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Legend Biotech, Regeneron Pharmaceuticals Inc, and Sanofi.
Program Schedule — Pacific Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Richardson

  • Long-term findings with daratumumab-containing front-line regimens; role in therapy for patients who are eligible and ineligible for transplant
  • Published data with novel daratumumab-based quadruplet regimens, such as RVd/daratumumab or KRd/daratumumab, for transplant-eligible patients; current nonresearch role and ongoing Phase III investigations
  • Mechanistic similarities and differences between daratumumab and isatuximab; implications for efficacy and tolerability
  • Key efficacy and safety findings from the Phase III GMMG-HD7 and Phase II GMMG-CONCEPT trials of isatuximab-containing quadruplet induction regimens for transplant-eligible patients; potential role of isatuximab in the up-front setting
  • Optimal maintenance approach for patients eligible and ineligible for transplant

MODULE 2: Integration of Novel Therapies into the Management of Relapsed/Refractory (R/R) MM — Dr Lonial

  • Updated findings from the Phase III ICARIA-MM and IKEMA studies of isatuximab with standard doublet regimens for R/R MM; FDA-approved indications for and optimal use of isatuximab
  • Early results with and ongoing evaluation of various subcutaneous formulations of isatuximab
  • Efficacy and safety data supporting the use of selinexor with a proteasome inhibitor for R/R MM; optimal incorporation into clinical practice and practical considerations
  • Early data with other selinexor-based combination strategies; ongoing Phase III XPORT-MM-031 trial of selinexor/pomalidomide/dexamethasone after at least 1 prior therapy
  • Key findings with belantamab mafodotin monotherapy for R/R MM; withdrawal from the US market and implications for therapeutic sequencing
  • Early data with and ongoing evaluation of belantamab mafodotin with other systemic therapies; potential role of this strategy

MODULE 3: Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM — Dr Raje

  • Compositional and mechanistic similarities and differences between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel); implications for efficacy and tolerability
  • Principal efficacy and safety results supporting the FDA approvals of ide-cel and cilta-cel for triple class-exposed MM; optimal selection of patients for CAR T-cell therapy
  • Data from the Phase III KarMMa-3 and CARTITUDE-4 trials of ide-cel and cilta-cel, respectively, in earlier lines of treatment
  • Ongoing trials evaluating BCMA-targeted CAR T-cell therapies after induction therapy, such as CARTITUDE-5, CARTITUDE-6, KarMMa-4 and KarMMa-9
  • Incidence, severity and management of class-effect toxicities observed with BCMA-targeted CAR T-cell therapies in patients with MM
  • Preliminary data and ongoing research with non-BCMA-targeted CAR T-cell platforms

MODULE 4: Bispecific Antibodies in the Treatment of MM — Dr Krishnan

  • Similarities and differences in the cellular targets and mechanisms of action among bispecific antibodies
  • Antitumor activity observed with teclistamab in the Phase I/II MajesTEC-1 study leading to its recent FDA approval for R/R MM; optimal incorporation into the treatment paradigm
  • Rate, depth and duration of response to elranatamab in the pivotal Phase II MagnetisMM-3 trial; FDA approval and current role
  • Key findings with other promising anti-BCMA bispecific antibody constructions, such as linvoseltamab, alnuctamab and ABBV-383, for heavily pretreated MM
  • Available efficacy and safety findings with non-BCMA-targeted bispecific antibodies for MM, such as talquetamab, cevostamab and forimtamig; FDA approval of talquetamab for patients with R/R MM after at least 4 prior therapies
  • Spectrum, incidence and severity of cytokine release syndrome and other toxicities with the various BCMA- and non-BCMA-directed bispecific antibodies; mitigation and management
  • Rationale for and early-phase data with bispecific antibodies in combination with other systemic therapies

MODULE 5: Other Novel Agents and Strategies Under Investigation for MM — Dr Orlowski

  • Biological rationale for targeting Bcl-2 in t(11;14)-positive MM
  • Recently presented results from the Phase III CANOVA study of venetoclax/dexamethasone versus pomalidomide/dexamethasone for t(11;14)-positive R/R MM
  • Early results with and ongoing studies of other venetoclax-based combinations for patients with MM
  • Current nonresearch role, if any, of venetoclax in the care of patients with R/R MM
  • Data documenting the activity and safety of the cereblon E3 ligase modulators iberdomide and mezigdomide in patients with heavily pretreated MM; ongoing evaluation and potential clinical roles
  • Other promising novel strategies in clinical development for patients with MM

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
At the conclusion of this activity, participants should be able to

  • Customize the selection of first-line therapy for patients with newly diagnosed MM, considering cytogenetic profile, eligibility for stem cell transplant, new research and other factors.
  • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM who are eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
  • Consider published research and other clinical factors in the best-practice selection, sequencing and combining of established agents and regimens for patients with relapsed/refractory MM.
  • Understand the mechanisms of action of and pivotal trial findings with recently FDA-approved novel therapies to facilitate their integration into MM management.
  • Evaluate the biological rationale for BCMA-directed chimeric antigen receptor T-cell therapy as a targeted strategy for MM, and identify patients for whom this novel approach should be considered.
  • Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and appropriately select patients for one of these treatments or a related clinical trial.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for MM, and appropriately counsel patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Krishnan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Janssen Biotech Inc; Speakers Bureau: Bristol Myers Squibb, Takeda Pharmaceuticals USA Inc; Stock Options/Ownership — Public Company: Bristol Myers Squibb. Dr Lonial — Advisory Committee and Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Board of Directors with Stock: TG Therapeutics Inc (no cancer agents currently); Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Novartis. Dr Orlowski — Advisory Committee: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, BioTheryX Inc, Bristol Myers Squibb, Karyopharm Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, Nanjing IASO Biotherapeutics, Neoleukin Therapeutics, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Sporos Bioventures, Takeda Pharmaceuticals USA Inc; Clinical Research Funding: Bristol Myers Squibb, CARsgen Therapeutics, Exelixis Inc, Heidelberg Pharma, Janssen Biotech Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Laboratory Research Funding: Asylia Therapeutics Inc, BioTheryX Inc, Heidelberg Pharma; Patents: Asylia Therapeutics Inc. Dr Raje — Advisory Committee: Caribou Biosciences Inc, Immuneel Therapeutics; Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Janssen Biotech Inc, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: bluebird bio. Dr Richardson — Advisory Committee: Bristol Myers Squibb, Celgene Corporation, GSK, Karyopharm Therapeutics, Oncopeptides, Sanofi; Research Grants: Bristol Myers Squibb, Celgene Corporation, Karyopharm Therapeutics, Oncopeptides, Takeda Pharmaceuticals USA Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, GSK, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, Legend Biotech, Regeneron Pharmaceuticals Inc, and Sanofi.

Omni San Diego Hotel
675 L Street
San Diego, CA 92101
Phone: (619) 231-6664

Meeting Room
Grand Ballroom (Level 2)

Directions
Located directly across from the San Diego Convention Center, where the 2023 ASH Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

There is no fee to participate in this hybrid event. For the in-person symposium in San Diego preregistration is required as seating is limited.

NOTICE: Registration for this event is independent of registration for the ASH Annual Meeting.

IN-PERSON Registration for clinicians in practice/healthcare professionals

Thank you for your interest in our CME program.†At this time†online†preregistration†is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION.†Our†Onsite Registration Desk will be open at†6:30 PM PT†on Friday, December†8th.†If you are interested in attending, please visit our registration desk located outside the†Grand Ballroom (Level 2)†of the†Omni San Diego†Hotel†(675 L Street).

Omni San Diego Hotel †is conveniently located 6 minutes (0.2 miles) from the San Diego Convention Center, where the 65th†ASH Annual Meeting is taking place. ASH will be providing complimentary shuttle service between the convention center and participating conference hotels. Shuttle schedule information will be made available on the ASH conference website and also posted in the lobby of participating hotels.

If you have any questions, please feel free to contact us via email at†Meetings@ResearchToPractice.com†or call (800) 233-6153.

NOTICE: Registration for this event is independent of registration for the ASH Conference.

LIVE WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.